We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best stocks to buy and ...

Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK515.00.

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...

Novo Holdings announced an investment in a $200M Series A launch financing for Swiss company Windward Bio. 1 The clinical stage drug development company is developing treatments for immunological ...

Diversified Trust Co increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

The oversubscribed Series A launch financing was co-led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, and joined by SR One, Omega Funds, RTW Investments, Qiming Venture Partners ...

COPENHAGEN, Denmark, Jan. 10, 2025 /PRNewswire/ -- Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio.

The newly emerged Swiss biotech’s series A financing was led by OrbiMed, Novo Holdings and Blue Owl Healthcare Opportunities, with participation from six other industry investors, according to a ...